Am­gen vet Marc de Garidel takes the helm at Cor­vidia; Pe­ter Green­leaf lands next CEO job at Cere­cor; Ed­ward Gu­daitis tapped to lead Acerus

→ Am­gen vet Marc de Garidel is tak­ing the helm at Cor­vidia Ther­a­peu­tics as the biotech wraps up a Phase II tri­al of its per­son­al­ized ther­a­py for chron­ic kid­ney dis­ease. Michael David­son, the found­ing CEO who de­signed the strat­e­gy to go af­ter small, ge­net­i­cal­ly de­fined pa­tient pop­u­la­tions, will re­main in the C-suite but fo­cus on the sci­ence. The Waltham, MA-based com­pa­ny may have launched less than two years ago, but it’s al­ready think­ing about its fu­ture com­mer­cial op­er­a­tions. De Garidel is ex­pect­ed to build the com­pa­ny much like how he helped grow Ipsen’s US op­er­a­tions as CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER